Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D de Wit, HJ Guchelaar, J den Hartigh… - Drug discovery today, 2015 - Elsevier
Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …
[引用][C] Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D de Wit, HJ Guchelaar, J den Hartigh… - Drug Discovery …, 2015 - cir.nii.ac.jp
Individualized dosing of tyrosine kinase inhibitors: are we there yet? | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学図書館の本をさがす …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学図書館の本をさがす …
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D de Wit, HJ Guchelaar, J den Hartigh… - Drug discovery …, 2015 - pubmed.ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) are registered at a fixed oral dose, despite their large
variability in pharmacokinetics (PK). Given that the evidence for a relation between drug …
variability in pharmacokinetics (PK). Given that the evidence for a relation between drug …
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D de Wit, HJ Guchelaar, J den Hartigh… - Drug Discovery …, 2015 - infona.pl
Tyrosine kinase inhibitors (TKIs) are registered at a fixed oral dose, despite their large
variability in pharmacokinetics (PK). Given that the evidence for a relation between drug …
variability in pharmacokinetics (PK). Given that the evidence for a relation between drug …
[引用][C] Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D Wit, J Hartigh, H Gelderblom, N Erp - 2015 - repository.ubn.ru.nl
Tyrosine kinase inhibitors (TKIs) are registered at a fixed oral dose, despite their large
variability in pharmacokinetics (PK). Given that the evidence for a relation between drug …
variability in pharmacokinetics (PK). Given that the evidence for a relation between drug …
[PDF][PDF] Individualized dosing of tyrosine kinase inhibitors–are we there yet?
D de Wit, HJ Guchelaar… - Drug …, 2015 - scholarlypublications …
Recently, a study that used pooled data of 168 patients with metastatic renal cell carcinoma
(mRCC) showed that patients with an area under curve (AUC) 0-24≥ 300 ng∙ hr/mL after 4 …
(mRCC) showed that patients with an area under curve (AUC) 0-24≥ 300 ng∙ hr/mL after 4 …
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D de Wit, HJ Guchelaar, J den Hartigh… - Drug Discovery …, 2014 - europepmc.org
Tyrosine kinase inhibitors (TKIs) are registered at a fixed oral dose, despite their large
variability in pharmacokinetics (PK). Given that the evidence for a relation between drug …
variability in pharmacokinetics (PK). Given that the evidence for a relation between drug …
[引用][C] Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D Wit, HJ Guchelaar, J Hartigh… - Drug …, 2015 - scholarlypublications …